285 related articles for article (PubMed ID: 34664091)
1. Differential role of residual metabolic tumor volume in inoperable stage III NSCLC after chemoradiotherapy ± immune checkpoint inhibition.
Unterrainer M; Taugner J; Käsmann L; Tufman A; Reinmuth N; Li M; Mittlmeier LM; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Manapov F
Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1407-1416. PubMed ID: 34664091
[TBL] [Abstract][Full Text] [Related]
2. Metabolic patterns on [
Holzgreve A; Taugner J; Käsmann L; Müller P; Tufman A; Reinmuth N; Li M; Winkelmann M; Unterrainer LM; Nieto AE; Bartenstein P; Kunz WG; Ricke J; Belka C; Eze C; Unterrainer M; Manapov F
Eur J Nucl Med Mol Imaging; 2023 Jul; 50(8):2466-2476. PubMed ID: 36951991
[TBL] [Abstract][Full Text] [Related]
3. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
4. The utility of
Kitajima K; Kawanaka Y; Komoto H; Minami T; Yokoi T; Kuribayashi K; Kijima T; Nakamura A; Hashimoto M; Kondo N; Hasegawa S; Yamakado K
Hell J Nucl Med; 2021; 24(3):186-198. PubMed ID: 34901959
[TBL] [Abstract][Full Text] [Related]
5. Are pretreatment 18F-FDG PET tumor textural features in non-small cell lung cancer associated with response and survival after chemoradiotherapy?
Cook GJ; Yip C; Siddique M; Goh V; Chicklore S; Roy A; Marsden P; Ahmad S; Landau D
J Nucl Med; 2013 Jan; 54(1):19-26. PubMed ID: 23204495
[TBL] [Abstract][Full Text] [Related]
6. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
[TBL] [Abstract][Full Text] [Related]
7. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
8. Nodal metabolic tumour volume on baseline
Alipour R; Bucknell N; Bressel M; Everitt S; MacManus M; Siva S; Hofman MS; Akhurst T; Hicks RJ; Iravani A
J Med Imaging Radiat Oncol; 2021 Oct; 65(6):748-754. PubMed ID: 34318603
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
10. Treatment patterns and prognosis of patients with inoperable stage III NSCLC after completion of concurrent chemoradiotherapy ± immune checkpoint inhibition: a decade-long single-center historical analysis.
Flörsch B; Taugner J; Käsmann L; Kenndoff S; Guggenberger J; Tufman A; Reinmuth N; Duell T; Belka C; Eze C; Manapov F
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3267-3276. PubMed ID: 35915184
[TBL] [Abstract][Full Text] [Related]
11. Concurrent/sequential versus sequential immune checkpoint inhibition in inoperable large stage III non-small cell lung cancer patients treated with chemoradiotherapy: a prospective observational study.
Käsmann L; Eze C; Taugner J; Nieto A; Hofstetter K; Kröninger S; Guggenberger J; Kenndoff S; Flörsch B; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
J Cancer Res Clin Oncol; 2023 Aug; 149(10):7393-7403. PubMed ID: 36939927
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of metabolic parameters measured by (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with small cell lung cancer.
Zhu D; Ma T; Niu Z; Zheng J; Han A; Zhao S; Yu J
Lung Cancer; 2011 Sep; 73(3):332-7. PubMed ID: 21292341
[TBL] [Abstract][Full Text] [Related]
13. Volume-Based Assessment With 18F-FDG PET/CT Improves Outcome Prediction for Patients With Stage IIIA-N2 Non-Small Cell Lung Cancer.
Hyun SH; Ahn HK; Ahn MJ; Ahn YC; Kim J; Shim YM; Choi JY
AJR Am J Roentgenol; 2015 Sep; 205(3):623-8. PubMed ID: 26295651
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
15. Validation of Independent Prognostic Value of Asphericity of
Rogasch JMM; Furth C; Chibolela C; Hofheinz F; Ochsenreither S; Rückert JC; Neudecker J; Böhmer D; von Laffert M; Amthauer H; Frost N
Clin Lung Cancer; 2020 May; 21(3):264-272.e6. PubMed ID: 31839531
[TBL] [Abstract][Full Text] [Related]
16. Predictive and Prognostic Role of Metabolic Response in Patients With Stage III NSCLC Treated With Neoadjuvant Chemotherapy.
Castello A; Toschi L; Rossi S; Finocchiaro G; Grizzi F; Mazziotti E; Qehajaj D; Rahal D; Lopci E
Clin Lung Cancer; 2020 Jan; 21(1):28-36. PubMed ID: 31409523
[TBL] [Abstract][Full Text] [Related]
17. Prognostic Value of Preradiotherapy (18)F-FDG PET/CT Volumetrics in Limited-Stage Small-Cell Lung Cancer.
Ong LT; Dunphy M; Foster A; Woo KM; Zhang Z; Perez CA; Pietanza CM; Rosenzweig KE; Gelblum DY; Rimner A; Wu AJ
Clin Lung Cancer; 2016 May; 17(3):184-8. PubMed ID: 26320828
[TBL] [Abstract][Full Text] [Related]
18. Significance of
Kim E; Wu HG; Keam B; Kim TM; Kim DW; Paeng JC; Kim HJ; Chang JH
Clin Lung Cancer; 2019 Jan; 20(1):e9-e23. PubMed ID: 30266585
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of volume-based FDG PET/CT parameters in patients with locally advanced pancreatic cancer treated with chemoradiation therapy.
Choi HJ; Lee JW; Kang B; Song SY; Lee JD; Lee JH
Yonsei Med J; 2014 Nov; 55(6):1498-506. PubMed ID: 25323885
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of
Ling T; Zhang L; Peng R; Yue C; Huang L
Front Immunol; 2022; 13():1014063. PubMed ID: 36466905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
